Compare BHC & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHC | HROW |
|---|---|---|
| Founded | N/A | 1998 |
| Country | Canada | United States |
| Employees | N/A | 373 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1996 | N/A |
| Metric | BHC | HROW |
|---|---|---|
| Price | $4.43 | $38.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $8.00 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 2.7M | 648.0K |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $4.61 | $31.62 |
| Revenue Next Year | N/A | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.33 | $28.54 |
| 52 Week High | $8.69 | $54.98 |
| Indicator | BHC | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 40.25 |
| Support Level | N/A | $37.81 |
| Resistance Level | $6.31 | $41.94 |
| Average True Range (ATR) | 0.15 | 2.32 |
| MACD | -0.03 | -0.68 |
| Stochastic Oscillator | 16.30 | 3.19 |
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.